Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
7Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Tenaya Therapeutics, Inc. (TNYA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
4Distinct source URLs
5High confidence
0.777Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from RGNX graph: Reciprocal relationship from TNYA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2…
SNYNF
Sanofi
72%
. We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these l…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from TNYA graph: . We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following lega…
Tenaya Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ALNYLAM
ALNYLAM
90%
Pursuant to the terms of the Collaboration Agreement, Alnylam will pay the Company an upfront payment of up to $10.0 million within thirty (30) days after Alnylam’s receipt of an invoice from the Company.
Reciprocal relationship from ALNY graph: Reciprocal relationship from TNYA graph: occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisf…
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Contract Liabilities Contract liabilities consist pr…
Reciprocal relationship from RGNX graph: Reciprocal relationship from TNYA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2…
SNYNF
Sanofi
72%
. We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these l…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from TNYA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from TNYA graph: Reciprocal relationship from SNYN…
CATALYST-PHARMS-INC
CATALYST-PHARMS-INC
62%
atio for its proposed indication is acceptable; • the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications o…
Tenaya Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TNYA-DEBT-13048
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
TNYA-DEBT
Debt stack $10.1M
90%
Market cache reports total debt of $10.1M.
TNYA-DEBT-13047
Warrants outstanding: 2289000
90%
xbrl warrant detail from xbrl 2025-12-31.
Tenaya Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Tenaya Therapeutics, Inc..
Tenaya Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
TNYA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 105 tracked holders.
Tenaya Therapeutics, Inc. Extended Supply Chain Network
